source
- FDA rejects Capricor's Duchenne cell therapy again, citing major trial flawsCapricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy was denied by the FDA for a second time. The agency highlighted significant issues with the trial design and data, le…
- Compass Pathways and Usona Institute vie for first FDA approval of a psilocybin depression therapyCompass Pathways and Usona Institute are both positioning themselves to become the first company with an FDA-approved psilocybin therapy for treatment-resistant depression. Compass has long been s…